While tumor concentrations were not evaluated at the higher (10 mg/kg) and lower (3 mg/kg) doses in the radiolabeled studies, the overlapping inhibition curves from HT29 xenograft tumor dose escalation regression profiles indicate the LAV- and HAV-ADCs were likely taken up and eliminated to a similar extent by a MET-mediated mechanism within the tumors (Fig 5). The gene discussed is MET; the disease is neoplasm.